TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

By Joe-Marc Chauvin, Ornella Pagliano, J. Fourcade, Zhaojun Sun, Hong Wang, C. Sander, J. Kirkwood, Tseng-Hui T Chen, M. Maurer, A. Korman and 1 more. Journal of Clinical Investigation, 2015

694 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/2ca4bdf8a2f7d6dbe9c92b9241f4f0ec22096441

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation (2016, background): “Lastly, the presence of Lag3+CD49b+IL-10-producing Tr1 cells has been associated with poor prognosis in colorectal cancer (Chen and Chen, 2014).”
Next generation of immune checkpoint therapy in cancer: new developments and challenges (2018, background): “Initial ex vivo and murine studies targeting dual blockade of TIGIT and either PD-1 or TIM-3 has shown a synergistic effect in immune cell proliferation, cytokine release, degranulation, and reversal of T cell exhaustion with subsequent tumor rejection and induction of protective memory responses [1”
T Cell Dysfunction in Cancer (2018, background): “Nevertheless, combined blockade of PD-1 and TIGIT on CD8+ TILs cultured in the presence of autologous tumor did show an additive effect in restoring effector functions (Chauvin et al., 2015).”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “Blockade of TIGIT shows significant synergy with PD-1 blockade and provides superior control of tumors and chronic viral infection in mouse models (229) and also has a role in human cancer (231), making it a high-priority clinical target.”